171 related articles for article (PubMed ID: 37899024)
1. Impact of the 3rd Edition of the Bethesda System for Reporting Thyroid Cytopathology on Grey Zone Categories.
Guerreiro SC; Tastekin E; Mourao M; Loureiro I; Eusebio R; Marques HP; Oznur M; Caliskan CK; Schmitt FC; Bongiovanni M; Canberk S
Acta Cytol; 2023; 67(6):593-603. PubMed ID: 37899024
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Approach to the Thyroid Bethesda Category III (AUS) in the Transition Zone Between 2nd Edition and 3rd Edition of The Bethesda System for Reporting Thyroid Cytopathology: Subcategorization, Nuclear Scoring, and More.
Bagıs M; Can N; Sut N; Tastekin E; Erdogan EG; Bulbul BY; Sezer YA; Kula O; Demirtas EM; Usta I
Endocr Pathol; 2024 Mar; 35(1):51-76. PubMed ID: 38280141
[TBL] [Abstract][Full Text] [Related]
3. Impact of the modification of the diagnostic criteria in the 2017 Bethesda System for Reporting Thyroid Cytopathology: a report of a single institution in Japan.
Higuchi M; Hirokawa M; Kanematsu R; Tanaka A; Suzuki A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1193-1198. PubMed ID: 30282887
[TBL] [Abstract][Full Text] [Related]
4. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
[TBL] [Abstract][Full Text] [Related]
5. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.
Zhao H; Guo H; Zhao L; Cao J; Sun Y; Wang C; Zhang Z
Cancer Cytopathol; 2021 Aug; 129(8):642-648. PubMed ID: 34139103
[TBL] [Abstract][Full Text] [Related]
6. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology.
Faquin WC; Wong LQ; Afrogheh AH; Ali SZ; Bishop JA; Bongiovanni M; Pusztaszeri MP; VandenBussche CJ; Gourmaud J; Vaickus LJ; Baloch ZW
Cancer Cytopathol; 2016 Mar; 124(3):181-7. PubMed ID: 26457584
[TBL] [Abstract][Full Text] [Related]
7. Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Is Not a Cytological Diagnosis, but It Influences Cytological Diagnosis Outcomes: A Systematic Review and Meta-Analysis.
Haaga E; Kalfert D; Ludvíková M; Kholová I
Acta Cytol; 2022; 66(2):85-105. PubMed ID: 34781293
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
[TBL] [Abstract][Full Text] [Related]
9. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B
Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595
[TBL] [Abstract][Full Text] [Related]
10. CLINICAL IMPACT OF NON-INVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES ON THE RISK OF MALIGNANCY IN THE BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: A META-ANALYSIS OF 14,153 RESECTED THYROID NODULES.
Vuong HG; Tran TTK; Bychkov A; Jung CK; Nakazawa T; Kakudo K; Katoh R; Kondo T
Endocr Pract; 2019 May; 25(5):491-502. PubMed ID: 30657357
[No Abstract] [Full Text] [Related]
11. Malignancy rate of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid nodules undergoing FNA in a suburban endocrinology practice: A retrospective cohort analysis.
Seagrove-Guffey MA; Hatic H; Peng H; Bates KC; Odugbesan AO
Cancer Cytopathol; 2018 Oct; 126(10):881-888. PubMed ID: 30335212
[TBL] [Abstract][Full Text] [Related]
12. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
13. Subcategorisation of AUS/FLUS thyroid lesions as per the 2017 Bethesda System for Reporting Thyroid Cytopathology: a retrospective study from a tertiary care centre analysing risk of malignancy (ROM) of the different subcategories.
Guleria P; Agarwal S; Iyer VK; Jain D; Mathur SR; Yadav D
J Clin Pathol; 2019 Nov; 72(11):771-777. PubMed ID: 31375535
[TBL] [Abstract][Full Text] [Related]
14. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients.
Arva NC; Deitch SG
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):753-60. PubMed ID: 25879311
[TBL] [Abstract][Full Text] [Related]
15. Fine needle aspiration of thyroid nodules in the pediatric population: a 12-year cyto-histological correlation experience at North Shore-Long Island Jewish Health System.
Lale SA; Morgenstern NN; Chiara S; Wasserman P
Diagn Cytopathol; 2015 Aug; 43(8):598-604. PubMed ID: 25728981
[TBL] [Abstract][Full Text] [Related]
16. Implementing noninvasive follicular thyroid neoplasm with papillary-like nuclear features may potentially impact the risk of malignancy for thyroid nodules categorized as AUS/FLUS and FN/SFN.
Li W; Sciallis A; Lew M; Pang J; Jing X
Diagn Cytopathol; 2018 Feb; 46(2):148-153. PubMed ID: 29193839
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound and cytological characteristics of non-invasive follicular thyroid neoplasm with papillary-like nuclear features compared to papillary carcinomas.
Boursier L; Clerc Urmes I; Garon J; Klein M; Demarquet L
Ann Endocrinol (Paris); 2020 Feb; 81(1):28-33. PubMed ID: 32081363
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and associated malignancy of Bethesda category III cytologies of thyroid nodules assigned to the "cytological atypia" or "architectural atypia" groups.
García Pascual L; Surralles ML; Morlius X; Garcia Cano L; González Mínguez C
Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):577-583. PubMed ID: 30262240
[TBL] [Abstract][Full Text] [Related]
20. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
